Kos Biotechnology Partners backs rare-disease platform Golden Age Health
What's the deal? Kos Biotechnology PartnersDealroom has a profile for this one. Try Dealroom → has made a strategic early-stage investment in Golden Age Health, a Singapore-headquartered specialty pharmaceutical platform that brings approved and near-approved rare and specialty disease medicines to underserved patients across Greater China, Southeast Asia, and the Gulf. The investment was made through Kos's inaugural fund, Kos BioVentures.
What's the endgame? Golden Age Health will use the capital to expand its commercial presence and portfolio in Greater China and Asia-Pacific, and to speed the cross-border flow of biotech innovation between Western markets and Asia.
Who's involved? Kos is a global life sciences investment firm based in New York and Athens, founded by Dr. Simos Simeonidis and Alex Tzoukas. It manages $125 million in assets and is backed by institutional investors including the Hellenic Development Bank of InvestmentsDealroom has a profile for this one. Try Dealroom →.
The key hire: Alex Tzoukas, managing partner and co-founder of Kos, will join Golden Age Health's board of directors. The firm said he will help scale the company's commercial infrastructure and portfolio, and build what he called "a two-way bridge that also brings high-potential Asian biotech innovation into Western clinical pipelines."
Why now? Golden Age Health is scaling its China business and maturing its partnership pipeline. It recently struck an exclusive 10-year deal to commercialise Innostellar's gene therapy LX-101 in Mainland China, and in February 2026 secured exclusive rights to commercialise ZTALMY, the first approved treatment for CDKL5 deficiency disorder in the country.
"Kos brings institutional capital and a vast network at the point where our China business is scaling and our partnership pipeline is maturing," said Yossi Ben Amram, co-founder and chief strategy and operations officer of Golden Age Health.
What could go wrong? The platform's model depends on navigating complex regulatory and commercial landscapes across multiple regions. Tzoukas said Golden Age Health has built an operational framework "that many Western biotech companies simply cannot navigate alone" — a strength, but also a reminder that access and reimbursement in these markets remain hard to solve.
The signal: The deal reflects investor appetite for the access and commercialisation side of rare-disease care, rather than drug discovery. A $82 million Series A for Mendra in January 2026 and renewed US rare-disease investment tied to the FDA's Priority Review Voucher program point to the same trend: capital is flowing to companies that get existing therapies to the patients who need them.
Read more: prnewswire.com
Image credit: Generated with Gemini
